These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 34644705)

  • 1. Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.
    Reiter FP; Ben Khaled N; Ye L; Zhang C; Seidensticker M; Op den Winkel M; Denk G; Geier A; De Toni EN
    Dig Dis; 2022; 40(5):565-580. PubMed ID: 34644705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
    Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
    Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
    Wong KM; King GG; Harris WP
    Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
    Bangaru S; Marrero JA; Singal AG
    Aliment Pharmacol Ther; 2020 Jan; 51(1):78-89. PubMed ID: 31747082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradigm shift in the treatment options of hepatocellular carcinoma.
    Su TH; Hsu SJ; Kao JH
    Liver Int; 2022 Aug; 42(9):2067-2079. PubMed ID: 34515412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials.
    Gamboa AC; Kooby DA; Maithel SK; Gamblin TC
    J Surg Oncol; 2024 Jan; 129(1):63-70. PubMed ID: 38059310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Progress in Systemic Therapy for Advanced Hepatocellular Carcinoma.
    Sadagopan N; He AR
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for the treatment of hepatocellular carcinoma.
    Ayoub WS; Jones PD; Yang JD; Martin P
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review.
    Pinter M; Jain RK; Duda DG
    JAMA Oncol; 2021 Jan; 7(1):113-123. PubMed ID: 33090190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, efficacy, and tolerability of immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.
    Brown ZJ; Gregory S; Hewitt DB; Iacono S; Choe J; Labiner HE; Pawlik TM
    Surg Oncol; 2022 Jun; 42():101748. PubMed ID: 35395582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.
    Liu TH; Shen YC; Cheng AL
    J Formos Med Assoc; 2022 Aug; 121(8):1371-1383. PubMed ID: 35400583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
    Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Status Quo and Development of Immunotherapy for Hepatocellular Carcinoma].
    Wang T; Wang WT
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 May; 54(3):692-698. PubMed ID: 37248607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
    Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
    Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):333-339. PubMed ID: 35403533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
    De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
    World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indonesian consensus on systemic therapies for hepatocellular carcinoma.
    Hasan I; Loho IM; Setiawan PB; Djumhana A; Purnomo HD; Siregar L; Gani RA; Sulaiman AS; Lesmana CRA
    Asia Pac J Clin Oncol; 2023 Feb; 19(1):263-274. PubMed ID: 35599455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma.
    Villarruel-Melquiades F; Mendoza-Garrido ME; García-Cuellar CM; Sánchez-Pérez Y; Pérez-Carreón JI; Camacho J
    World J Gastroenterol; 2023 May; 29(17):2571-2599. PubMed ID: 37213397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.